SETDB1 promotes tumour progression through multiple mechanisms, including gene silencing [16, 17], epithelial-mesenchymal transition (EMT) [18], drug resistance [12, 19], methylation and activation of AKT [20, 21], immune cell function and tumour immunotherapy [22, 23]. Here, AKT1 is linked to neoplasm.